Nuffield Health Cheltenham Hospital, is the latest hospital to offer Single Dose Intraoperative Radiotherapy (SD-IORT) for early breast cancer with the Oncotherapy Resources Ltd (ORL) managed service.
Nuffield Health Cheltenham Hospital joins the growing number of independent hospitals across the UK in offering suitable early stage breast cancer patients the choice of single dose Intraoperative radiotherapy (SD-IORT) by utilising the ORL managed service.
Experienced consultant breast surgeons Charlie Chan, Fiona Court and James Bristol will be offering IORT at Nuffield Health Cheltenham Hospital. Patients who would benefit from SD-IORT include those that are 50 years or older with small low-grade tumours. SD-IORT has considerable benefits for the patient in comparison to whole breast radiotherapy. For most patients, SD-IORT eliminates the need for post-operative radiotherapy, avoiding the inconvenience, disruption and expense of attending daily hospital appointments for several weeks.
The ORL managed service enables hospitals throughout the UK to offer IORT to eligible patients without the need to travel long distances for treatment. ORL aims to bring managed mobile services closer to the patients.
ORL use the Xoft Axxent Electronic Brachytherapy (eBx) System to deliver SD-IORT during breast-conserving surgery (BCS) to treat early stage breast cancer.
About Oncotherapy Resources Ltd (ORL) – an Xstrahl Group company
ORL are the UK distributor for the Xoft® System and the providers of managed Intraoperative radiotherapy services aiming to improve access for patients. In the UK, breast cancer patients have benefited from ORL’s SD-IORT in several hospitals including Spire Montefiore Hospital in Brighton, Nuffield Health Brighton Hospital, Spire Thames Valley and Spire Hospital in Bristol. The treatment is also already available at many other hospitals throughout England and Wales. ORL’s single dose radiotherapy treatment is expertly delivered at the point of surgery, offering patients a convenient and effective treatment experience. For more information: www.oncotherapyresources.com
About Xoft® (a subsidiary of iCad)
The Xoft® System is FDA cleared, CE marked and licensed in a growing number of countries including the UK for the treatment of cancer.[i],[ii] Xoft® System is a simple-to-use, portable SD-IORT device, which utilises a disposable miniature x-ray tube (50kV). Minimal radiation shielding is required, avoiding the need to adjust operating theatres and enabling medical personnel to remain with the patient during treatment. More than 3,000 breast cancer patients globally have already been treated with the Xoft® Axxent System.[iii]
[i] U.S. Food and Drugs Administration. Tab 5 510 (k) Summary k090914. July 2009. Available at: http://www.accessdata.fda.gov/cdrh_docs/pdf9/k090914.pdf. Last accessed 10 March 2016.
[ii] Medical Devices Safety Service. Certificate of CE Marking for Xoft Inc. 2 December 2011. Available on request.
[iii] Xoft, Inc. iCAD announces more than 3,000 early-stage breast cancer patients treated with the one-day breast cancer treatment. Available at: http://www.xoftinc.com/icad-announces-more-than-3%2c000-early-stage-breast-cancer-patients-treated.html Last accessed 11 April 2017.